Trials / Completed
CompletedNCT01790087
ANX-188 Thorough QT/QTc Study in Healthy Volunteers
A Four Period, Four-Arm, Crossover Design, Randomized, Placebo and Active Controlled Study for the Evaluation of the Effect of Therapeutic and Supratherapeutic Single-Dose ANX-188 on the QT/QTc Intervals in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Mast Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study has been designed in compliance with the ICH-E14 guideline (2005) to evaluate the effect of ANX-188 at therapeutic and supratherapeutic concentrations on cardiac repolarization, specifically, Fridericia's QT-Interval (QTcF)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANX-188 Therapeutic Dose | |
| DRUG | ANX-188 Supratherapeutic dose | |
| DRUG | Saline | |
| DRUG | Moxifloxacin |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2013-04-01
- Completion
- 2013-06-01
- First posted
- 2013-02-13
- Last updated
- 2015-05-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01790087. Inclusion in this directory is not an endorsement.